



## Continuum of hepatitis C care in France: A 20-year cohort study

Coralie Hermetet, Frédéric Dubois, Catherine Gaudy-Graffin, Yannick Bacq, Bernard Royer, Christophe Gaborit, Louis D'alteroche, Jean Claude Desenclos, Philippe Roingeard, Leslie Grammatico-Guillon, et al.

### ► To cite this version:

Coralie Hermetet, Frédéric Dubois, Catherine Gaudy-Graffin, Yannick Bacq, Bernard Royer, et al.. Continuum of hepatitis C care in France: A 20-year cohort study. PLoS ONE, 2017, 12 (8), 10.1371/journal.pone.0183232 . hal-01774662

**HAL Id: hal-01774662**

**<https://univ-tours.hal.science/hal-01774662>**

Submitted on 8 Dec 2023

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.


RESEARCH ARTICLE

# Continuum of hepatitis C care in France: A 20-year cohort study

Coralie Hermetet<sup>1</sup>, Frederic Dubois<sup>2,3,4</sup>, Catherine Gaudy-Graffin<sup>2,3</sup>, Yannick Bacq<sup>5</sup>, Bernard Royer<sup>4</sup>, Christophe Gaborit<sup>1</sup>, Louis D'Alteroche<sup>5</sup>, Jean Claude Desenclos<sup>6</sup>, Philippe Roingeard<sup>2,7</sup>, Leslie Grammatico-Guillon<sup>1,2\*</sup>

**1** SIMEES, CHRU de Tours, Laboratoire de Santé Publique, Université François Rabelais, Tours, France, **2** INSERM U966, Université François Rabelais et CHRU de Tours, Tours, France, **3** Service de Bactériologie-Virologie-Hygiène, CHRU de Tours, Tours, France, **4** UC-IRSA, Département 37, La Riche, France, **5** Service de d'Hépatogastro-entérologie, CHRU de Tours, Tours, France, **6** Direction Scientifique, InVS, Saint-Maurice, France, **7** Laboratoire de Biologie Cellulaire, CHRU de Tours, Tours, France

\* [leslie.guillon@univ-tours.fr](mailto:leslie.guillon@univ-tours.fr)



## Abstract

### Background

Hepatitis C virus (HCV)-infected patients require a specific continuum of care (CoC) from HCV screening to treatment. We assessed CoC of HCV-infected patients in a longitudinal study.

### Methods

We established a cohort of subjects undergoing HCV screening (high alanine aminotransferase levels or risk factors) during preventive consultations at a French regional medical center from 1993 to 2013. Patients were considered to be HCV-infected if HCV RNA was detected in their serum. CoC was assessed as described by Viner *et al.* (*Hepatology* 2015): Stage 1, HCV screening; Stage 2, HCV RNA testing; Stage 3, continuing care; Stage 4, antiviral treatment. Cox multivariate analysis was performed to identify factors favoring CoC, defined as at least one course of antiviral treatment.

### Results

In total, 12,993 HCV tests were performed and 478 outpatients were found to be HCV-seropositive. We included 417 seropositive patients, after excluding false positives and patients lost to follow-up. The baseline characteristics of the patients were: sex ratio (M/F) 1.4; mean age 38.5 years; intravenous drug use (IDU) in 55%; and 28% in unstable social situations, estimated by the EPICES deprivation score. Antiviral treatment was initiated for 179 (42.9%) of the 379 (90.9%) patients attending specialist consultations. CoC was associated with screening after 1997 (HR 2.0, 95%CI 1.4–2.9), age > 45 years (HR 1.5, 95%CI 1.02–2.3), patient acceptance of care (HR 9.3, 95%CI 5.4–16.10), specialist motivation for treatment (HR 10.9, 95%CI 7.4–16.0), and absence of cancer (HR 6.7, 95%CI 1.6–27.9). Other comorbid conditions, such as depression and IDU, were not associated with CoC.

## OPEN ACCESS

**Citation:** Hermetet C, Dubois F, Gaudy-Graffin C, Bacq Y, Royer B, Gaborit C, et al. (2017) Continuum of hepatitis C care in France: A 20-year cohort study. PLoS ONE 12(8): e0183232. <https://doi.org/10.1371/journal.pone.0183232>

**Editor:** Yuri E. Khudiyakov, Centers for Disease Control and Prevention, UNITED STATES

**Received:** March 1, 2017

**Accepted:** August 1, 2017

**Published:** August 29, 2017

**Copyright:** © 2017 Hermetet et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

**Data Availability Statement:** All relevant data are available within the paper and its Supporting Information files.

**Funding:** The authors received no specific funding for this work.

**Competing interests:** Dr Bacq has served as a speaker for Roche, Gilead, or Bristol-Myers Squibb, and was invited to a liver meeting by AbbVie. L Grammatico-Guillon has served once as a speaker for AbbVie.

## Conclusions

Our 20-year cohort study reveals the real-life continuum of care for HCV-infected patients in France. The number of patients involved in HCV care after positive testing was substantial due to the organization of healthcare in France. An improved CoC along with new direct-acting antivirals should help to decrease chronic HCV infection.

## Introduction

The emergence of hepatitis C virus (HCV) over recent decades has created a major public health burden [1,2], with approximately 180 million people around the world infected [3–5]. Acute infection progresses to chronic hepatitis in 55 to 85% of cases, and chronic HCV infection leads to severe complications (end-stage cirrhosis, hepatocellular carcinomas, liver transplants) [3–7]. A 1994 population-based survey estimated the prevalence of HCV infection in France to be 1.1% of the population [8,9]. The French health authorities launched a public-health response including primary prevention, the promotion of HCV screening, access to treatment, and research [10]. In 2004, an apparent decrease in prevalence was reported, with an estimated 250,000 infected people (0.84%) [11]. However, the proportion of HCV-infected individuals who are aware of their infection status is just over 50% [4,7,12], despite the investment in primary prevention, social marketing campaigns to promote screening, and the mobilization of healthcare professionals in France against HCV infection. Silent HCV infection may affect 80,000 people in France that have yet to be tested (former intravenous drug users (IDU) [13,14] and other at-risk groups, such as migrants and prison inmates [15,16]).

The treatment of HCV infection has improved significantly over the last two decades [12], especially with the recent development of direct-acting antiviral drugs (DAA) with shorter treatment duration and fewer side effects than previous drugs. This has considerably improved the prognosis of HCV patients, with cure rates exceeding 90% for all genotypes [17–19]. With these new developments, the eradication of HCV infection is foreseeable [20], perhaps by 2030 [21] if HCV-infected patients can be identified and treated early enough [22,23]. In this context, assessment of the continuum of care (CoC) from infection to cure is of strategic importance for policy implementation and evaluation [7]. For example, several simple, inexpensive operational interventions have been demonstrated to substantially improve engagement along the HCV CoC (e.g., promoting HCV testing and nurse-led educational interventions) [24].

This cohort study, based on a 20-year risk-based screening program within a population health system, provides an overview of the CoC for HCV-infected patients in France, during the different treatment eras, and investigates the factors associated with access to CoC.

## Methods

### Study population

A cohort of HCV-infected individuals was built through a social security screening program implemented at a medical center in France, between 1993 and 2013. This social security medical center, run by the French National Health Insurance System, offers patients with social security coverage, unemployed individuals, and welfare recipients a biomedical examination every five years [8]. The district served by this medical center has 591,000 inhabitants, 85% of whom are covered by the French social security system.

## Subject inclusion

The medical check-up at the medical center includes a series of biological tests, including serum alanine aminotransferase (ALT), followed by a clinical examination. The medical center has established routine testing of serum alanine aminotransferase (ALT) levels as a guide for selective testing for hepatitis C during the medical checkup [8]. Subjects were selected for HCV screening using serological tests for HCV antibodies (Ab) (enzyme immunoassay (EIA) or first- to third-generation assays, depending on the recommendations during the period concerned), as specified in the protocol established and followed by nurses and medical doctors. Every arriving medical fellow, nurse, or practitioner had to be trained before beginning preventive consultation. All individuals with high ALT levels were tested: ALT levels of 1.2-fold, or more, above the normal value according to age and sex [8,25,26]. HCV testing was also performed on patients without high ALT levels, but with risk factors for HCV infection, such as IDU, blood transfusion, and known exposure to HCV. All EIA-positive samples were verified using a third-generation strip immunoblot assay (RIBA HCV strip immunoblot assay, available up to 2007, notably RIBA-3, Chiron Corp., Emeryville, CA, then replaced by inno-LiPa HCV Score, Innogenetics, Ghent, Belgium). All individuals undergoing medical check-ups between 1993 and 2013 and eligible for HCV testing were screened and included in the cohort if the first and control HCV Ab tests were positive.

During the study period, 274,510 medical check-ups were performed: 12,993 (4.7%) HCV Ab tests were performed with 718 positive cases, corresponding to 478 different patients. We finally included 417 individuals seropositive for HCV by the second Ab test (step 1 of CoC) in the cohort, due to the exclusion of spontaneous HCV cure ( $N = 31$ ) and false-positive HCV Ab test results (Fig 1).

The examination center immediately informed the patient's GP of a positive HCV Ab test, requiring a specific follow-up by the general practitioner (GP). The confirmatory test was carried out by the patient's GP, who was responsible for the CoC of the positive HCV patients, especially confirmatory RNA testing and referral to a specialist. Patients were considered to be chronically infected with HCV if a positive result was obtained in an HCV RNA test (test carried out according to the recommendations of the period in a biological laboratory routinely performing the RNA test), corresponding to step 2 of the CoC. Follow-up and outcome variables were obtained for these patients by requesting information from the patient's GP and/or hepatologist if necessary.


## Data collection

Age, sex, medical history, alcohol, tobacco, and drug abuse, and the deprivation score, based on the French EPICES index [27], were collected at inclusion. Two time periods were defined according to treatment eras: interferon alone up to 1997 (p1); and p2, beginning with the advent of combined treatment with interferon and ribavirin. The HCV genotype was determined when RNA amplification was possible (InnoLiPa, HCV Score, Innogenetics, Ghent, Belgium according to current guidelines).

## Outcome and explanatory variables

The HCV CoC was defined as: stage 1, HCV screening; stage 2, positive test for HCV RNA; stage 3, continuing care, defined by a specialist consultation; stage 4, care and antiviral treatment. HCV cure was defined by a prolonged period ( $> 6$  months) of negative PCR results.

The factors associated with CoC were analyzed by constructing two binary variables from the information obtained from medical records or a medical interview: willingness of the physician to treat the patient according to treatment recommendations based on comorbid



**Fig 1. Selection of the study population for assessment of the HCV infection CoC.** HCV: Hepatitis C Virus; CoC: continuum of care; Ab: antibody.

<https://doi.org/10.1371/journal.pone.0183232.g001>

conditions, medical history, and the patient's motivation to be cured according to the concerns or reluctance of the patient to start treatment, based on the conclusions drawn by the physician.

### Statistical analysis

The CoC for HCV infection, from stage 1 to 4, was described for all patients included over the 20-year period, then by treatment era. The case fatality rate (overall and directly due to HCV) was calculated as a density rate, with the number of deaths as the numerator and the person-

time contribution (time between step 1 and the most recent information for each patient) of all included patients chronically infected with HCV (Step 2) as the denominator.

We performed multivariate analysis of the factors associated with the occurrence of a specialist consultation within one year of screening, using a logistic regression model. The end-point was the one-year of follow-up, corresponding to a manageable interval between the diagnosis of HCV viremia and counseling.

Kaplan Meier estimates were used to describe access to treatment (Step 4) during follow-up. The endpoint of the survival analyses was December 31, 2013. All possible explanatory variables for consultation occurrence were first tested in a bivariate survival model. Variables of interest, with a  $p$  value  $< 0.2$  by bivariate analysis were included in the multivariate analysis. Age and sex were systematically included. Cox proportional hazards models were then used to assess the effects of various confounding factors, as well as the time period, on the likelihood of CoC success (Step 3). Hazard ratios (HRs) and their 95% confidence intervals [95%CI] were calculated. We assessed the proportionality of hazards and used the log rank test to compare survival curves.

Statistical analysis was performed using SAS software, version 9.1 (SAS).

## Ethics approval

This study was approved by the CNIL, Commission Nationale de l'Informatique et des Libertés, Paris, France, no. 1739731 and the District CNIL of Tours University Hospital no. 2015\_015. All patients included in this study were personally informed by a written document of the treatment of the data, as well as their right to object and access the data, according to articles L.1121-1 and R1121-2 of the French Code of Public Health. The need for individual patient consent was waived by the Research Ethics Committee as the study was considered to be a quality assurance project (authorization no. 2015 013).

## Results

### Characteristics of the study population

We included 417 patients in the cohort (Fig 1), distributed between the treatment periods as follows: 57% up to 1997 and 40% from 1998. The estimated prevalence in the medical center was 3.2%. Data was censored for 19% of patients ( $N = 78$ ) during the study period due to lost-of-follow-up.

The mean age of the patients at the time of the first test was 38.5 years (range 11–79 years). The sex ratio was 1.38 and 29% of cases were socially deprived. IDU was reported for 55% of the HCV-infected patients. The most frequently identified comorbid conditions were: alcohol abuse, liver diseases, and depression. Only five coinfections with HIV were identified. Less than 5% of the data were missing for almost all variables in the study database, with less than 3% missing for treatment period ( $N = 12$ ), but 17% for the social deprivation score.

Seventy patients were already aware that they were seropositive for HCV from a previous check-up. HCV genotypes were determined for 172 patients (41%). Genotype 1 (subtypes a and b) was the most common (55%), followed by genotypes 3 (31%) and 4 (8%).

### Characteristics of the continuum of care

The demographic profile of the individuals at each stage of the HCV continuum of care is shown in Table 1. The proportion of male patients was greater among those receiving HCV treatment (stage 4) than among those at earlier stages of the continuum ( $p < 0.05$ ). The proportion of HCV patients did not differ significantly between age groups. Most patients were less than 45 years old, except at stage 2 (more than 55% over 45 years) but this difference was not statistically significant.

**Table 1. Baseline characteristics of the patients of the cohort, 1993–2013, Indre-et-Loire, France.**

Patient characteristics		Screening period			p
		Total N(%)	Period 1 N(%)	Period 2 N(%)	
Total		405 (100)*	238 (57.0)	167 (40.0)	
Sex					
Female		175 (42)	95 (39.9)	75 (44.9)	NS
	Male	242 (58)	143 (60.1)	92 (55.1)	
Age at first positive test (range)		38.5 (11–79)	35.8 (11–73)	42.3 (19–79)	< 0.05
Social deprivation					
Yes		118 (28.3)	73 (30.6)	43 (25.7)	NS
	No	229 (54.9)	127 (53.4)	95 (56.9)	
	Missing data	70 (16.8)	38 (16)	29 (17.4)	
Mode of infection					
	IDU	228 (54.7)	132 (55.4)	89 (53.3)	NS
	Blood transfusion	87 (20.8)	58 (24.4)	25 (15)	< 0.05
	Mixed	6 (1.4)	3 (1.3)	3 (1.8)	NC
	Other	82 (19.7)	38 (16)	44 (26.3)	< 0.05
	Missing data	14 (3.4)	7 (2.9)	6 (3.6)	NC
First test					
	Examination center	225 (54.0)	99 (41.6)	126 (75.4)	< 0.05
	Check-up	70 (16.8)	53 (22.3)	17 (10.2)	< 0.05
	Abnormal transaminase results	25 (6.0)	17 (7.1)	7 (4.2)	NS
	Medical history	51 (12.2)	38 (16)	11 (6.6)	< 0.05
	Clinical symptoms	20 (4.8)	17 (7.1)	3 (1.8)	< 0.05
	Missing data	26 (6.2)	14 (5.9)	3 (1.8)	NC
Comorbid conditions					
		86 (20.6)	50 (21)	35 (21)	NS
	Alcohol abuse				
	Depression	60 (14.4)	31 (13)	23 (13.8)	NS
	Other liver diseases	49 (11.8)	29 (12.2)	20 (12)	NS
	Thyroid diseases	14 (3.4)	9 (3.8)	5 (3)	NS
	Hematological diseases	10 (2.4)	5 (2.1)	5 (3)	NS
	Cardiovascular diseases	11 (2.6)	8 (3.4)	3 (1.8)	NS
	Mental problems	15 (3.6)	9 (3.8)	3 (1.8)	NS
	Infectious diseases	10 (2.4)	6 (2.5)	3 (1.8)	NS
	Immunological diseases	6 (1.4)	3 (1.3)	3 (1.8)	NS
	Neurological diseases	7 (1.7)	3 (1.3)	4 (2.4)	NS
	Diabetes mellitus	17 (4.1)	9 (3.8)	8 (4.8)	NS
	Non-liver cancers	17 (4.1)	10 (4.2)	7 (4.2)	NS

\*Period data missing: N = 12

Period 1: 1993–1997; Period 2: 1998–2013

IDU: intravenous drug use

<https://doi.org/10.1371/journal.pone.0183232.t001>

There were no apparent differences across the continuum for the deprivation index, at-risk group, or first test location. The population of patients at stage 1 was mostly male (83%), as at step 4, whereas the proportion of female patients was higher at stages 2 and 3 (Table 2).

Over the entire study period, most patients reached stage 3 of the CoC (90%), and 43% had at least one antiviral treatment for HCV. During period p1, 64% of the patients reached step 3, with only 10% obtaining treatment within p1. However, 103 (45%) patients included in the first period p1 received treatment for HCV infection during period p2. During p2, 167 patients were included, 90% of whom reached step 3, with 42% obtaining antiviral treatment. The case

**Table 2. Demographics of individuals at of the various stages of the hepatitis C testing to care and treatment.**

Demographics		Total N = 417 (100%)	Stage of HCV testing and care				P value
			Stage 1	Stage 2	Stage 3	Stage 4	
			Ab +/-Ag N = 12 (%)		In care		
					Yes		
			Ab+ RNA N = 27 (%)	No Antiviral treatment Ab + RNA N = 199 (%)	Antiviral treatment Ab + RNA N = 179 (%)		
Sex	Male	242 (100)	10 (4.1)	16 (6.6)	101 (41.7)	115 (47.6)	< 0.05
	Female	175 (100)	2 (1.1)	11 (6.3)	98 (56.0)	64 (36.6)	
Age group	≤ 45 years	303 (100)	9 (3.0)	15 (5.0)	142 (46.8)	137 (45.2)	NS
	> 45 years	102 (100)	2 (2.0)	9 (8.8)	50 (49.0)	41 (40.2)	
	Missing data	12 (100)	1 (8.3)	3 (25.0)	7 (58.4)	1 (8.3)	
Deprivation index	Yes	118 (100)	2 (1.7)	6 (5.1)	54 (45.7)	56 (47.5)	NS
	No	229 (100)	8 (3.5)	19 (8.3)	105 (45.8)	97 (42.4)	
	Missing data	70 (100)	2 (2.9)	2 (2.9)	40 (57.1)	26 (37.1)	
At-risk population	IDU	228 (100)	7 (3.1)	16 (7.0)	108 (47.4)	97 (42.5)	NS
	Transfusion	87 (100)	1 (1.2)	3 (3.4)	44 (50.6)	39 (44.8)	
	Mixed	6 (100)	0 (0)	0 (0)	3 (50.0)	3 (50.0)	
	Other	82 (100)	1 (1.2)	7 (8.5)	39 (47.6)	35 (42.7)	
	Missing data	14 (100)	3 (21.4)	1 (7.1)	5 (35.7)	5 (37.7)	
First screening	Medical examination center	225 (100)	8 (3.5)	17 (7.6)	110 (48.9)	90 (40.0)	NS
	Check-up	70 (100)	1 (1.5)	4 (5.7)	30 (42.8)	35 (50.0)	
	Abnormal transaminase results	25 (100)	0 (0)	0 (0)	10 (40.0)	15 (60.0)	
	Medical history	51 (100)	2 (3.9)	2 (3.9)	24 (47.1)	23 (45.1)	
	Clinical symptoms	20 (100)	0 (0)	2 (10.0)	9 (45.0)	9 (45.0)	
	Missing data	26 (100)	1 (3.8)	2 (7.7)	16 (61.6)	7 (26.9)	

Stage 1, HCV screening; Stage 2, positive test for HCV RNA; Stage 3, continuing care, defined by a specialist consultation; Stage 4, care and antiviral treatment; Ab = Antibody

<https://doi.org/10.1371/journal.pone.0183232.t002>

fatality rate was 7.4/1,000 person-years (31 deaths). Specific case fatality directly due to HCV infection was 4.3/1,000 person-years (18 deaths).

Prolonged remission was observed in 65% of the 179 patients undergoing antiviral treatment during follow-up, mostly (95%) during p2. At the endpoint, 150 patients had been followed, but had not yet received any treatment. However, the doctors responsible for patient care did not consider treatment to be useful for 60% of the patients in regular care, mostly because of the absence of fibrosis/cirrhosis, or the presence of only early stage fibrosis.

## Factors associated with consultation within one year of HCV diagnosis

The factors associated with progression to stage 3 of the CoC within one year of screening by multivariate analysis were: performance of the first positive test at the examination center (OR = 2.2), screening during p2 (OR = 2.6), social deprivation (OR = 3.2), and age over 45 years at the time of screening (OR = 1.9) (Table 3). In contrast, a first positive test for HCV at a check-up and being at-risk were significantly associated with a longer time to specialist consultation.

## Factors associated with the initiation of antiviral treatment

We plotted Kaplan-Meier curves for the CoC (Fig 2). Approximately 15% of patients were treated in the first two years after inclusion (censored data corresponded to 50% of the total

**Table 3. Occurrence of a specialist consultation within one year after the first positive test for HCV, assessed by logistic regression (N = 205).**

Population characteristics		Individuals		Bivariate analysis	Multivariate analysis
		N	%	OR (95% CI)	OR (95% CI)
Sex	Female	100	48.7	1	-
	Male	105	51.2	0.60 (0.40–0.91)	
Age	≤ 45 years	139	67.8	1	
	> 45 years	66	32.2	2.36 (1.44–3.87)	1.88 (1–3.52)
Social deprivation		81	39.5	3.03 (1.84–4.97)	3.16 (1.83–5.44)
At-risk population					
IDU		102	49.8	0.51 (0.33–0.78)	-
Blood transfusion		55	26.8	1.67 (1.01–2.76)	-
Other		51	24.9		
First positive screening					
At the medical examination center		141	68.8	2.95 (1.92–4.54)	2.18 (1.32–3.61)
Check-up		23	11.2	0.36 (0.21–0.63)	0.36 (0.19–0.68)
Increase in ALT levels		10	4.9		
Risk factors		17	8.3	0.44 (0.23–0.83)	0.40 (0.19–0.86)
Clinical symptoms		10	4.9		
Screening period					
1993 to 1997		95	43.3	1	
1998 to 2013		110	53.7	2.77 (1.81–4.24)	2.55 (1.50–4.33)
Comorbid conditions					
Alcohol dependence		36	17.6	0.57 (0.36–0.96)	-
Depression		26	12.7		
Other liver diseases		23	11.2		
Non-liver cancers		11	5.4		
Psychiatric disorders		4	1.9		


<https://doi.org/10.1371/journal.pone.0183232.t003>

cohort). Male patients, patients screened during period 2, and patients over the age of 45 years had shorter intervals between screening and the occurrence of stage 4 of the CoC (Fig 2). Approximately 70% of the patients reaching stage 3 had a consultation with a specialist during the first two years after HCV screening. Female patients, patients screened during period 2, and older patients reached stage 3 more rapidly. We found that 20% of patients obtained treatment within two years of specialist consultation. Men were treated earlier than women and patients screened during p2 were treated more rapidly than those screened during period 1, whereas age at the first HCV positive test did not seem to be linked to the absence of CoC progression (Fig 2).

In the Cox model, the identification of factors associated with treatment occurrence in the bivariate analysis was performed on 345 patients, whereas the multivariate analysis was based on the 319 patients without missing data for the explicative variables (Table 4). Hence, the factors significantly associated with a first antiviral treatment were age over 45 years (HR 1.54), screening after 1997, absence of cancer, the physician's view that treatment was necessary (HR 10.0), and the patient's willingness to be treated (HR 9.3) (Table 4).

## Discussion

This is the first 20-year study of the CoC for chronic HCV infection to be carried out at the population level in France. We found that 3.2% of subjects targeted for HCV screening from the French general population had HCV infection. This is three-fold higher than other French



**Fig 2. Kaplan-Meier curves for CoC up to step 4 (antiviral treatment), by sex, period, and age: 1993–2013.** HCV: Hepatitis C Virus; CoC: continuum of care of HCV-infected patients between HCV testing and antiviral treatment; M: male; F: female P1: screening period 1993–1997; P2: screening period 1998–2013.

<https://doi.org/10.1371/journal.pone.0183232.g002>

prevalence estimations based on targeted populations. Over two decades of the study, the frequency of anti-HCV antibodies in this population decreased, HCV screening activity increased substantially, and the proportion of HCV tests yielding positive results decreased markedly after 2000. A substantial number of patients who tested positive for HCV entered the CoC (stages 3 and 4 accounted for 90% of HCV-infected patients), showing the positive impact of this targeted operational intervention, with a higher proportion of patients receiving counseling and treatment in the second decade. Thus, this public health screening intervention may have expedited progression through the CoC, improving engagement along the HCV CoC (e.g., by alerting GPs of a positive test), as recently demonstrated in a systematic review and meta-analysis for viral hepatitis CoC [24].

Understanding the reasons for patients entering the CoC is critical for modifying public health policy and physician practices to increase the number of patients treated. Our findings highlighted key points for progression through the CoC. Effective organization facilitates progression through a CoC and health policies that favor HCV screening of the at-risk population improve the CoC (e.g., the timely identification of at-risk patients due to targeted screening) which must be further enhanced in the near future with the availability of new active antivirals.

Advances in HCV therapy have ushered in a new era in chronic hepatitis treatment [24]. Individuals must be engaged and retained in care to maximize the effects of the new DAAs [5,7,12,20,28,29]. Our French medical center appears to effectively promote progression through the CoC, with 43% of patients reaching one antiviral treatment by the end of our study versus only 27% in a recent US study [7]. The varying results between the French and US studies may be accounted for by differences in HCV screening policies between the two countries. First, our protocol associated the medical questionnaire with the medical interview performed in a two-step sequence (the first by a nurse and the second by a medical doctor,

**Table 4. Multivariate analysis (Cox model) of antiviral treatment initiation after HCV diagnosis.**

Population characteristics		Individuals		Bivariate analysis	Multivariate analysis (N = 319)
		N = 345	(100%)	HR (95% CI)	HR (95% CI)
Sex	Female	148	42.9	1	-
	Male	197	57.1	2.03 (1.36–3.02)	-
Age	≤ 45 years	260	75.4	1	1
	> 45 years	85	24.6	1.20(0.78–1.85)	1.54 (1.02–2.31)
Social deprivation <i>missing data</i>		106	57	36.8	1.25 (0.85–1.87)
At-risk population					
IDU				0.84 (0.58–1.22)	-
Blood transfusion		78	22.6	0.93 (0.61–1.42)	-
Other		71	20.6	1.43 (0.93–2.21)	-
First positive screening					
At medical examination center		194	56.2	2.35 (1.52–3.34)	
Check-up		61	17.7	0.57 (0.32–1.01)	
Increase in ALT levels		21	6.1	1.09 (0.53–2.24)	
Risk factor				1.60(0.61–4.17)	
Clinical symptoms		16	4.6	0.39 (0.09–1.56)	
Screening period					
1993 to 1997		196	56.8	1	1
1998 to 2013		149	43.2	1.82 (1.31–2.52)	1.97 (1.36–2.85)
Comorbidity					
Alcohol dependence		76	22.0	1.06 (0.69–1.69)	-
Depression		49	14.2	0.81 (0.47–1.39)	-
Other liver diseases		47	13.6	0.75 (0.41–1.37)	-
Absence of cancer		329	95.4	2.62 (0.83–8.26)	6.67 (1.60–27.9)
No psychiatric disorders		336	97.4	4.21 (0.59–30.23)	-
Willingness of physician to initiate antiviral treatment		210	60.9	3.86 (2.77–5.37)	10.86 (7.38–15.97)
Willingness of the patient to be treated		81	23.5	2.99 (1.84–4.85)	9.30 (5.42–15.97)

<https://doi.org/10.1371/journal.pone.0183232.t004>

both trained in the HCV screening protocol), associated with the biological data (ALT levels) detected most concerned individuals. Second, this could be due to the effective organization at the examination center, which carries out centralized HCV testing and immediately informs the patient's GP to facilitate testing for the presence of HCV RNA. Third, the long study period, with patients coming back several times to the center, helped practitioners convince the patients to consult their GP and begin the CoC with a specialist. These findings suggest that targeted screening, based on a questionnaire addressing only the most common risk factors, such as that used by the social security medical examination center, may be of little added value if the physicians involved in the testing procedure are not sufficiently well trained, as recently shown in the international literature [8,26]. Our testing procedure corresponds to the approach currently proposed by the American authors to US health policy-makers [7]. Too few at-risk patients are appropriately screened in the USA and too few infections are confirmed and managed, despite the recommendations for HCV screening.

A large part of the better progression through the CoC in France may also be explained by the French public health policy, especially the reimbursement of medical care costs by the French National Health Insurance. Finally, these key elements of the CoC, along with the current DAA era, aid the promotion of HCV screening in at-risk populations and better professional coordination of healthcare.

This study has some limitations. Our population was composed of apparently at-risk people targeted for HCV screening, giving higher HCV prevalence. The General population was not represented. However, the association of the medical questionnaire and biological data in our protocol helped to detect most of the concerned individuals, even if any investigation based on a risk factor screening method may miss some patients. Moreover, our cohort demonstrated a protocol for testing and following at-risk subjects for hepatitis C. Furthermore, this study lacked some information, due to missing data, such as the stage of fibrosis. However, we analyzed a very large population, providing reliable data on the French at-risk population. Indeed, our report is the largest study of the CoC of Hepatitis C in a French population.

In conclusion, our population-based cohort study reveals the real-life CoC for HCV-infected patients in a French district. The number of patients involved in HCV care after positive testing was substantial, due to focused screening and a good organization of healthcare. An improved CoC, along with new direct-acting antivirals, should help to decrease chronic HCV infection and its complications, thereby increasing survival and reducing the burden of HCV infection.

## Supporting information

**S1 Fig. Distribution of care continuum stages for HCV-positive patients in *Indre-et-Loire*, 1993–2013 (N = 417).**

S1a: Continuum of care during p1 (1993–1997) for patients screened during p1

S1b: Continuum of care during p2 (1998–2013) for patients screened during p1

S1c: Continuum of care during p2 (1998–2013) for patients screened during p2

S1d: Continuum of care during p2 for patients screened during p1 or p2 (1993–2013).  
(JPG)

**S2 Fig. Kaplan-Meier curves for CoC up to step 3 (specialist consultation), by sex, period, and age: 1993–2013. M: male; F: female.**  
(TIFF)

**S1 Dataset. HCV cohort database.**  
(XLSX)

## Acknowledgments

We thank all the medical doctors and biologist teams involved in the development of the cohort of patients infected by HCV.

## Author Contributions

**Conceptualization:** Frederic Dubois, Catherine Gaudy-Graffin, Bernard Royer, Jean Claude Desenclos, Philippe Roingeard.

**Data curation:** Frederic Dubois, Yannick Bacq, Bernard Royer, Louis D’Alteroche.

**Formal analysis:** Coralie Hermetet, Christophe Gaborit, Philippe Roingeard, Leslie Grammatico-Guillon.

**Investigation:** Frederic Dubois, Bernard Royer, Louis D’Alteroche.

**Methodology:** Christophe Gaborit, Leslie Grammatico-Guillon.

**Project administration:** Coralie Hermetet, Catherine Gaudy-Graffin, Bernard Royer, Leslie Grammatico-Guillon.

**Resources:** Frederic Dubois, Catherine Gaudy-Graffin, Yannick Bacq, Bernard Royer, Louis D'Alteroche, Philippe Roingeard, Leslie Grammatico-Guillon.

**Software:** Christophe Gaborit, Leslie Grammatico-Guillon.

**Supervision:** Jean Claude Desenclos, Philippe Roingeard, Leslie Grammatico-Guillon.

**Validation:** Yannick Bacq, Leslie Grammatico-Guillon.

**Visualization:** Louis D'Alteroche, Jean Claude Desenclos, Philippe Roingeard.

**Writing – original draft:** Coralie Hermetet, Catherine Gaudy-Graffin, Leslie Grammatico-Guillon.

**Writing – review & editing:** Catherine Gaudy-Graffin, Yannick Bacq, Jean Claude Desenclos, Philippe Roingeard, Leslie Grammatico-Guillon.

## References

1. Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. *Lancet Infect Dis*. 2005; 5: 558–567. [https://doi.org/10.1016/S1473-3099\(05\)70216-4](https://doi.org/10.1016/S1473-3099(05)70216-4) PMID: 16122679
2. Marcellin P, Asselah T, Boyer N. Fibrosis and disease progression in hepatitis C. *Hepatology*. 2002; 36: S47–S56. <https://doi.org/10.1053/jhep.2002.36993> PMID: 12407576
3. Chen SL, Morgan TR. The natural history of hepatitis C virus (HCV) infection. *Int J Med Sci*. 2006; 3: 47–52. PMID: 16614742
4. Delarocque-Astagneau E, Meffre C, Dubois F, Pioche C, Le Strat Y, Roudot-Thoraval F, et al. The impact of the prevention programme of hepatitis C over more than a decade: the French experience. *J Viral Hepat*. 2010; 17: 435–443. <https://doi.org/10.1111/j.1365-2893.2009.01196.x> PMID: 19780936
5. Dhumeaux D, Marcellin P, Lerebours E. Treatment of hepatitis C. The 2002 French consensus. *Gut*. 2003; 52: 1784–1787. PMID: 14633963
6. Smith BD, Morgan RL, Beckett GA, Falck-Ytter Y, Holtzman D, Teo C-G, et al. Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945–1965. *MMWR Recomm Rep*. 2012; 61: 1–32.
7. Viner K, Kuncio D, Newbern EC, Johnson CC. The continuum of hepatitis C testing and care. *Hepatology*. 2015; 61: 783–789. <https://doi.org/10.1002/hep.27584> PMID: 25348499
8. Dubois F, Desenclos JC, Mariotte N, Goudeau A. Hepatitis C in a French population-based survey, 1994: seroprevalence, frequency of viremia, genotype distribution, and risk factors. The Collaborative Study Group. *Hepatology*. 1997; 25: 1490–1496. <https://doi.org/10.1002/hep.510250630> PMID: 9185773
9. Meffre C, Le Strat Y, Delarocque-Astagneau E, Dubois F, Antona D, Lemasson J-M, et al. Prevalence of hepatitis B and hepatitis C virus infections in France in 2004: social factors are important predictors after adjusting for known risk factors. *J Med Virol*. 2010; 82: 546–555. <https://doi.org/10.1002/jmv.21734> PMID: 20166185
10. Brody H. Hepatitis C. *Nature*. 2011; 474: S1–S1. <https://doi.org/10.1038/474S1a> PMID: 21666726
11. Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. *Hepatology*. 2013; 57: 1333–1342. <https://doi.org/10.1002/hep.26141> PMID: 23172780
12. Pol S, Corouge M. Treatment of hepatitis C: Perspectives. *Med Mal Infect*. 2014; <https://doi.org/10.1016/j.medmal.2014.07.015> PMID: 25174659
13. Edlin BR. Hepatitis C screening: getting it right. *Hepatology*. 2013; 57: 1644–1650. <https://doi.org/10.1002/hep.26194> PMID: 23239521
14. Marcellin P, Pequignot F, Delarocque-Astagneau E, Zarski J-P, Ganne N, Hillon P, et al. Mortality related to chronic hepatitis B and chronic hepatitis C in France: evidence for the role of HIV coinfection and alcohol consumption. *J Hepatol*. 2008; 48: 200–207. <https://doi.org/10.1016/j.jhep.2007.09.010> PMID: 18086507
15. Almasio PL, Babudieri S, Barbarini G, Brunetto M, Conte D, Dentico P, et al. Recommendations for the prevention, diagnosis, and treatment of chronic hepatitis B and C in special population groups

- (migrants, intravenous drug users and prison inmates). *Dig Liver Dis.* 2011; 43: 589–595. <https://doi.org/10.1016/j.dld.2010.12.004> PMID: 21256097
16. Negro F. Epidemiology of hepatitis C in Europe. *Dig Liver Dis.* 2014; 46 Suppl 5: S158–164. <https://doi.org/10.1016/j.dld.2014.09.023> PMID: 25453870
  17. Lawitz E, Poordad FF, Pang PS, Hyland RH, Ding X, Mo H, et al. Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naïve and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial. *Lancet.* 2014; 383: 515–523. [https://doi.org/10.1016/S0140-6736\(13\)62121-2](https://doi.org/10.1016/S0140-6736(13)62121-2) PMID: 24209977
  18. Mishra P, Murray J, Birnkrant D. Direct-acting antiviral drug approvals for treatment of chronic hepatitis C virus infection: Scientific and regulatory approaches to clinical trial designs. *Hepatology.* 2015; 62: 1298–1303. <https://doi.org/10.1002/hep.27880> PMID: 25953139
  19. Noell BC, Besur SV, deLemos AS. Changing the face of hepatitis C management—the design and development of sofosbuvir. *Drug Des Devel Ther.* 2015; 9: 2367–2374. <https://doi.org/10.2147/DDDT.S65255> PMID: 25987834
  20. Bansal S, Singal AK, McGuire BM, Anand BS. Impact of all oral anti-hepatitis C virus therapy: A meta-analysis. *World J Hepatol.* 2015; 7: 806–813. <https://doi.org/10.4254/wjh.v7.i5.806> PMID: 25914781
  21. Rapport\_Prise\_en\_charge\_Hepatitis\_2014-DHUMEAUX.pdf [Internet]. Available: [http://www.sante.gouv.fr/IMG/pdf/Rapport\\_Prise\\_en\\_charge\\_Hepatitis\\_2014.pdf](http://www.sante.gouv.fr/IMG/pdf/Rapport_Prise_en_charge_Hepatitis_2014.pdf)
  22. Brouard C, Le Strat Y, Larsen C, Jauffret-Roustide M, Lot F, Pillonel J. The undiagnosed chronically-infected HCV population in France. Implications for expanded testing recommendations in 2014. *PLoS ONE.* 2015; 10: e0126920. <https://doi.org/10.1371/journal.pone.0126920> PMID: 25961575
  23. Vermeiren APA, Dukers-Muijters NHTM, van Loo IHM, Stals F, van Dam DW, Ambergen T, et al. Identification of hidden key hepatitis C populations: an evaluation of screening practices using mixed epidemiological methods. *PLoS ONE.* 2012; 7: e51194. <https://doi.org/10.1371/journal.pone.0051194> PMID: 23236452
  24. Zhou K, Fitzpatrick T, Walsh N, Kim JY, Chou R, Lackey M, et al. Interventions to optimise the care continuum for chronic viral hepatitis: a systematic review and meta-analyses. *The Lancet Infectious Diseases.* [https://doi.org/10.1016/S1473-3099\(16\)30208-0](https://doi.org/10.1016/S1473-3099(16)30208-0)
  25. Desenclos JC, Dubois F, Mariotte N, Goudeau A. [Should hepatitis C be screened? Analysis of oriented screening strategies for hepatitis C virus infection]. *Gastroenterol Clin Biol.* 1997; 21: S25–32. PMID: 9161511
  26. Gaudy C, Thevenas C, Tichet J, Mariotte N, Goudeau A, Dubois F. Usefulness of the hepatitis C virus core antigen assay for screening of a population undergoing routine medical checkup. *J Clin Microbiol.* 2005; 43: 1722–1726. <https://doi.org/10.1128/JCM.43.4.1722-1726.2005> PMID: 15814991
  27. Sass et al. InVS | BEH n° 14 (4 avril 2006). Le score Epices: un score individuel de précarité. Construction du score et mesure des relations avec des données de santé, dans une population de 197 389 personnes. [Internet]. [cited 25 Aug 2015]. Available: <http://www.invs.sante.fr/beh/2006/14/>
  28. Chavalitdhamrong D, Tanwandee T. Long-term outcomes of chronic hepatitis C patients with sustained virological response at 6 months after the end of treatment. *World J Gastroenterol.* 2006; 12: 5532–5535. <https://doi.org/10.3748/wjg.v12.i34.5532> PMID: 17006994
  29. Afdhal N, Reddy KR, Nelson DR, Lawitz E, Gordon SC, Schiff E, et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. *N Engl J Med.* 2014; 370: 1483–1493. <https://doi.org/10.1056/NEJMoa1316366> PMID: 24725238